High blood levels of the protein CX3CL1, a pro-inflammatory immune signal that appears to be associated with blood vessel inflammation, can accurately discriminate microscopic polyangiitis (MPA) and granulomatosis with polyangiitis (GPA) patients with active disease from those without, a study found. Importantly, high CX3CL1 levels were found to increase the…
Argenx has decided not to go ahead with its development plans for efgartigimod as a potential treatment for ANCA-associated vasculitis (AAV) after the therapy failed to show beneficial effects in late-stage clinical trials of two other autoimmune diseases. Efgartigimod is approved in the U.S. in two formulations for…
Amgen is planning to launch a Phase 3 clinical trial testing Tavneos (avacopan) — its approved therapy for adults with ANCA-associated vasculitis (AAV) — in combination with a standard regimen of rituximab or cyclophosphamide in children and adolescents with active AAV. That’s according to a company press release…
Sinonasal symptoms, as assessed with 22-item Sinonasal Outcome Test (SNOT-22), a patient-reported questionnaire, are more severe when ANCA-associated vasculitis (AAV) is active than during remission, a study shows. Sinonasal symptoms are those that affect the nose and the sinuses, that is, the air-filled cavities around the eyes and nose.
Patrys’ PAT-DX1 and PAT-DX3, two DNA-targeting antibodies known as deoxymabs, can suppress production of the antimicrobial webs implicated in ANCA-associated vasculitis (AAV) without weakening other immune responses, according to preclinical work. These webs, called neutrophil extracellular traps (NETs), are made up of a scaffold of DNA and enzymes…
Having microscopic polyangiitis (MPA) or granulomatosis with polyangiitis (GPA) — the two most common types of ANCA-associated vasculitis (AAV) — better determines patients’ clinical features and outcomes than the type of AAV-driving, self-reactive antibodies they have. That’s according to a study in Spain that showed that GPA was an…
ANCA-associated vasculitis (AAV) patients receiving a cumulative dose of at least 935 mg of glucocorticoids over six months are more likely to see clinically meaningful side effects, according to a study using calculations based on the Glucocorticoid Toxicity Index (GTI). The findings suggest the GTI, which considers the frequency…
Recruitment is continuing in three countries for a Phase 1b/2a clinical trial testing Alpine Immune Sciences’ povetacicept in adults with autoimmune conditions affecting the kidneys, including ANCA-associated vasculitis (AAV). Called RUBY-3 (NCT05732402), the early study is designed to enroll an estimated 56 patients, ages 18 and older,…
The Renal Risk Score may be a better histopathologic classification model than Berden for predicting long-term loss of kidney function in people with ANCA-related vasculitis (AAV) who have glomerulonephritis, an inflammation of the kidneys’ filtering units, a study finds. Incorporating the renal risk score into clinical decision-making could help…
The Kidney Disease: Improving Global Outcomes (KDIGO) work group has released an updated practice guideline based on developments in how best to manage ANCA-associated vasculitis (AAV) associated with inflammation or damage to the kidneys. The guideline now offers advice on the use of lower doses of…
Get regular updates to your inbox.